Healthcare Recapitalization: Minority, Majority and Dividend Recaps Explained
A healthcare recapitalization changes who owns the company or how it is financed, without a full exit. A minority recap sells a non-controlling stake. A majority recap sells control, and the owner rolls equity for a second payout. A dividend recap borrows against EBITDA and distributes the cash.
Pick by what you want to keep. A minority recap gives partial liquidity and keeps operating control. A majority recap pays the most cash now and brings acquisition capital. A dividend recap fits only if cash flow can carry the debt through a reimbursement cut.
Equity percentage alone does not settle control. The operating agreement does, through board seats, consent rights and voting agreements. An owner who sells 35% can still lose the final word on the decisions that set exit value.
Investor demand follows spending. The CMS National Health Expenditure fact sheet reports that US health spending grew 7.2% to $5.3 trillion in 2024, 18.0% of GDP. CMS projects physician and clinical services spending will grow 5.5% a year on average from 2025 to 2034.
The recap decision table: control, cash and debt side by side
| Minority recap | Majority recap | Dividend recap | |
|---|---|---|---|
| Control after close | Owner holds majority equity. Board seats and consent rights decide how much control that carries | Investor takes it | Owner keeps it, within lender covenants |
| Who funds the cash | Growth fund, family office, physician investors, strategic | PE sponsor or strategic equity, plus acquisition debt at the new holding company | Bank or private credit lender |
| Cash to owner at close | Price per unit × units sold (secondary portion only), less seller costs | Purchase price less rollover, less any existing debt repaid and seller costs | Debt raised less financing fees |
| New debt | None | Acquisition debt at the holding company or its borrowing subsidiary | All of the distribution, on the operating company |
| Second payout | Later sale of the remaining stake | Rolled equity at the sponsor's exit | Owner keeps 100% of future upside |
| What the owner gives up | Veto rights, information rights, exit timing | Control, budget authority, exit timing | Covenant headroom and free cash flow |
| Regulatory exposure | State transaction review where governance rights shift control | Antitrust, state transaction review, Medicare enrollment changes | Lower, since ownership does not change |
| Best fit | Growing owner who wants liquidity and to keep running the company | Owner ready to hand off who wants platform capital | Stable cash flow, low existing debt, owner wants full ownership |
Answer these five questions in order:
- Do you want to run the company for five or more years? If no, a majority recap or a full sale. If yes, keep going.
- Do you need growth capital or personal liquidity? Growth capital points to a primary minority raise. Personal liquidity points to a secondary minority sale or a dividend recap.
- Can cash flow carry debt service, capex, taxes and your own distributions through a reimbursement cut? If no, rule out the dividend recap.
- Will you accept vetoes on dilution, sale price and new debt? If no, rule out the minority recap.
- Does the investor need to own part of the clinical entity? If state ownership rules block that, the deal moves into an MSO structure. See how MSOs work.
Recap readiness: what to fix before you take a meeting
Every recap prices off adjusted EBITDA, and every buyer or lender rebuilds that number in diligence. The owner who arrives with it already defended keeps more of the price.
| Item | Why it moves the outcome | What good looks like |
|---|---|---|
| Quality of earnings report | Buyers and lenders discount add-backs they cannot verify | Sell-side QoE completed before the first term sheet |
| Owner and physician compensation | Normalized pay sets EBITDA and post-close comp | Market-rate comp schedule for every owner and producer |
| Payer mix and concentration | A single fee schedule cut can break a debt covenant or a valuation | Revenue by payer for three years, with contract terms |
| Real estate | Owned property can be sold separately or leased back at market rent | Real estate in a separate entity with a market-rate lease |
| Cap table and agreements | Unclear ownership or old buy-sell terms stall closing | Clean cap table, current operating agreement, consents mapped |
| Provider retention | Rollover value depends on producers staying | Employment terms and restrictive covenants in place for every key provider |
| Compliance file | Billing and referral issues become indemnity and escrow | Coding audit and referral arrangement review on file |
| Enrollment and licensing history | Prior ownership changes and license terms can set the closing date | Medicare enrollment dates, prior change-of-ownership dates and licenses by state |
How recaps play out by segment
Segment decides whether an owner gets a platform recap or an add-on price. Deal counts below come from the Private Equity Stakeholder Project's 2025 review of PE-backed healthcare deals in calendar 2025. PESP draws on PitchBook and LevinPro HC and calls its count a likely underestimate. Pricing figures come from different datasets with different methods, each labeled in its cell: indicative ranges, deal medians and public sector multiples. Do not compare pricing across rows.
| Segment | Deal activity (source, population, period) | Pricing signal (source, population, date) | Structural issue that shapes the recap |
|---|---|---|---|
| Health IT | 151 PE deals in 2025, the most active subsector (PESP) | 21.27x EV/EBITDA, 115 listed US companies (Damodaran, NYU Stern, Jan 2026) | Fewer clinical ownership limits than provider segments |
| Dental | 149 PE deals in 2025, 95% of them add-ons by PE-owned platforms (PESP) | DSO platforms 9 to 11x, add-ons 5 to 8x, indicative ranges (Sikich, Q3 2026 update) | Most owners sell into a platform and roll into equity they do not control |
| Outpatient care | 148 PE deals in 2025, 119 of them add-ons. Dermatology 24, eye care 22, oncology 9 (PESP data reported by Becker's ASC Review) | Physician practices 5 to 13x across four EBITDA bands, indicative ranges (Sikich, Q3 2026 update) | Clinical ownership rules often push the deal into an MSO structure |
| Ambulatory surgery centers | Counted within outpatient care by PESP | Single-specialty 5 to 8x, multispecialty 6 to 10x, regional operators 11 to 17x, indicative. Median ASC multiple 7.9x in 2025 (Sikich, Q3 2026 update) | Regional scale earns the higher band |
| Home health and hospice | Fewer closings in 2026 than 2025 (Sikich, Q3 2026 update) | Enhabit take-private at 10.2x, small agencies typically mid-single digits (Sikich, Q3 2026 update) | Prior ownership change dates can affect the timing of a majority recap |
| Behavioral health | 56 PE deals in 2025 (PESP) | No segment median in these sources. All healthcare services control deals: 9.6x EBITDA median, 68 deals with positive EBITDA (BuckheadFMV, Jan 2023 to Oct 2026) | State transaction reviews can set the timeline |
| Hospitals | 56 hospital transactions announced in 2026 through Q3. All of 2025 had 46, the lowest annual count since Kaufman Hall began tracking in 2011 (Kaufman Hall data reported by Becker's Hospital Review) | 8.86x EV/EBITDA, 31 listed US companies (Damodaran, Jan 2026) | Nearly 43% of hospitals were operating at a loss as of August 2026, and divestitures were nearly one-third of Q3 2026 deals (Kaufman Hall Q3 2026 M&A report release, Oct 13, 2026) |
Minority recap: a non-controlling stake sold, vetoes granted
The owner sells a minority stake through a secondary sale of existing units, a primary issue of new units, or both. Secondary dollars go to the owner. Primary dollars stay in the company to fund growth. Write the split into the term sheet, because only the secondary portion is liquidity.
Minority capital in healthcare comes from growth equity funds, physician investors, strategics and family offices. A family office investing from its own balance sheet usually has no fixed fund life. Others invest through vehicles with set terms, so ask which kind of capital is on the other side. See how family offices invest in healthcare. To see which healthcare companies have raised private capital and roughly when, search Form D notices on SEC EDGAR full-text search.
| Minority investor type | Typical hold horizon | What it will push for | Where owners get surprised |
|---|---|---|---|
| Growth equity fund | Set by the fund's life | Put right, drag-along after a set period, board seat | Forced exit timing near the end of the fund |
| Family office, own balance sheet | Usually open-ended | Distribution policy, information rights, consent on new debt | Expectation of regular cash yield |
| Physician investors | Often tied to practice tenure | Governance seats, buy-sell terms on departure | Valuation formula for departing partners |
| Strategic partner | Long, often with a path to control | Right of first refusal or a call option | A call option that caps the owner's exit price |
Selling under 50% leaves the owner with majority equity. It does not by itself leave the owner with control. The investor protects its position with board seats, voting agreements and negative controls, meaning consent rights that stop the majority from acting alone. A broad consent list can also bring a state transaction review into play. Expect consent rights over:
- New equity issuance or any dilutive round
- A sale of the company below a set multiple or price floor
- New debt above a stated leverage ratio
- Owner compensation and related-party contracts, including real estate leases
- Acquisitions above a dollar cap
- Amendments to the operating agreement
- A put right after a set number of years if no exit has occurred
Distribution policy belongs on the same list. A minority investor has no say over discretionary distributions unless the documents give it one. One structure ties the investor's payout to revenue at a margin agreed from the company's history. Hypothetical structure, our arithmetic: on $25.0 million of revenue, an agreed 15% margin and a 35% stake, the investor's annual distribution is $25.0M × 15% × 35% = $1.31 million. The owner gets predictability. The investor is protected if owner compensation creeps up and absorbs profit. Agree on the margin before you agree on the stake size.
Majority recap: control sold, rolled equity for a second bite
The mechanics run through a new holding company. The sponsor contributes cash equity, the owner contributes rollover equity, and the holding company or its borrowing subsidiary raises acquisition debt. The holding company then buys the operating company. The owner receives the purchase price less the rollover. Cash at close is the first payout. The rolled stake is the second, paid when the sponsor sells or recapitalizes again.
Most of the volume is add-ons. PESP's 2025 review tracked 1,029 PE-backed healthcare deals in 2025: 151 leveraged buyouts, 664 add-ons and 214 growth investments, across 420 platform companies and 708 investment firms. Ten of the 18 platforms with the most deals in 2025 were dental companies.
The platform versus add-on distinction drives the economics. A platform owner typically negotiates a board seat and a larger rollover. An add-on owner more often takes a purchase price and a smaller rollover into equity someone else controls. In Sikich's Q3 2026 indicative ranges for dental, platforms trade at 9 to 11x EBITDA and add-ons at 5 to 8x. Our arithmetic from those ranges puts the gap at 1 to 6 turns, depending on where each deal lands in its band. An owner close to platform scale should run a process that includes sponsors looking for a new platform, not only the platforms looking for add-ons.
Five terms set the value of the rollover:
| Term | What it does to the owner's second bite |
|---|---|
| Equity class | Common sits behind preferred at exit |
| Sponsor preferred return | Paid before common shares in the gain |
| Management fees to the holdco | Reduce cash available for debt paydown |
| How add-ons are funded | New equity dilutes the owner's percentage. New debt reduces equity value at exit. The worked example below prices both |
| Drag-along rights | Let the sponsor set exit timing and price |
Run the numbers in the rollover equity calculator before you agree to a rollover percentage.
Home health and hospice. Pull the agency's Medicare enrollment date and every prior change-of-ownership date before you sign an LOI. A recent ownership change can decide whether a majority recap works now or has to wait.
Dividend recap: new debt, one distribution, 100% ownership kept
The company borrows against its EBITDA and distributes the proceeds to owners. No equity changes hands. The owner keeps control and all future upside. The company carries the debt service.
See the healthcare capital stack chart.
Sikich's Q3 2026 update reports that entry leverage on PE-backed healthcare services buyouts edged up to 5.2x EBITDA in 2025. That is a sponsor number, backed by a sponsor's equity cushion and acquisition plan. An owner-run company should size a dividend recap to fixed charge coverage under stress, not to buyout leverage.
Interest coverage (EBITDA ÷ interest) is the quick screen. Fixed charge coverage is the test lenders write into covenants, because it also counts principal, capex, taxes and, in many definitions, distributions to owners. Test both in the debt capacity calculator. Before signing a commitment letter, confirm:
- Total debt to EBITDA after the distribution
- Interest coverage and fixed charge coverage at today's rate and at a stressed rate
- Covenant definitions: maximum leverage, fixed charge coverage, restricted payments, and whether owner distributions count as a fixed charge
- Scheduled amortization and any excess cash flow sweep
- Payer concentration and exposure to a single fee schedule cut
- Capex and acquisitions the debt service will crowd out
- Personal guarantees and their release conditions
Smaller practices often use bank debt for a related move, buying out a retiring partner instead of distributing cash. The SBA 7(a) program, the SBA's main small business loan program, sets a loan size limit that can change. A loan within that limit can fit a partner buyout at a smaller practice, but generally not a dividend recap the size of the $12.0 million example modeled below. Confirm current program limits with your lender.
2026 pricing: what a recap stake is worth by size and segment
Recaps price off the same control multiples as sales. A minority stake is then negotiated against them. None of the datasets below measures minority-stake pricing, and BuckheadFMV excludes minority stakes outright. Each row covers a different population and period. Read across a row, not down the column.
| Benchmark | Multiple | Type | Population | Source and date |
|---|---|---|---|---|
| Healthcare M&A, 2024 / 2025 / 2026 YTD through Q3 | 14.5x / 13.0x / 11.6x EV/EBITDA | Median | All healthcare M&A with disclosed multiples | PitchBook data reported by Sikich, Q3 2026 update |
| Healthcare M&A, trailing 12 months | 12.7x EV/EBITDA | Median | Same population | PitchBook data reported by Sikich, Q3 2026 update |
| PE-backed healthcare services buyouts, 2025 | 13.6x EBITDA (13.5x in 2024) | Median | PE buyouts with implied target EBITDA of roughly $33 million | Sikich, Q3 2026 update |
| Physician practices by EBITDA: under $1M / $1M to $3M / $3M to $5M / over $5M | 5 to 7x / 7 to 9x / 9 to 11x / 11 to 13x | Indicative range | Physician practice deals | Sikich, Q3 2026 update |
| Healthcare services control deals | 9.6x EBITDA (10.1x excluding distressed sales) | Median | 68 of 187 control transactions that disclosed positive EBITDA | BuckheadFMV, Jan 2023 to Oct 2026 |
| Closed small-business sales, healthcare: under $500K SDE / $10M+ EBITDA | 3.4x SDE (n=182) / 12.9x EBITDA (n=17) | Median | Closed small-business sales by deal size | Axia Growth, data as of Oct 28, 2026 |
| Public Healthcare Support Services / Hospitals / Healthcare IT | 11.17x / 8.86x / 21.27x EV/EBITDA | Sector multiple | Listed US companies, all sizes | Damodaran, NYU Stern, January 2026 |
Market medians. The 13.6x median describes PE buyouts of companies with roughly $33 million of EBITDA, far larger than most practices. All medians in the table are backward-looking figures from closed deals, not forecasts. A practice with $4 million of EBITDA does not price off them.
Control deals by size. BuckheadFMV's study covers 187 control transactions announced from January 2023 through October 2026, each with a disclosed or court-approved price from SEC filings, state transaction filings or bankruptcy court approvals. Only 68 disclosed positive EBITDA, so the 9.6x median rests on that subset. Within that subset, deals above $200 million traded at a median 11.2x EBITDA and deals below $10 million at 2.8x. The study page does not show how many deals fall in each size band, so the small-deal median may rest on very few deals. Treat it as directional. The pattern still suggests that size can move the multiple more than a segment label.
Public comps. Damodaran's January 2026 data covers listed companies, which are larger and freely traded. A private company prices at a discount to those figures, and the BuckheadFMV and Axia size bands show how steep that gets at small scale. Use public comps as a reference point, not a price.
See the healthcare multiples by segment and size chart.
Small deals. In Axia Growth's healthcare table of closed small-business sales (data as of Oct 28, 2026), businesses under $500K of seller's discretionary earnings (SDE) sold at a median 3.4x SDE. Those above $10 million of EBITDA sold at 12.9x EBITDA. SDE adds back the owner's pay, so an SDE multiple runs lower than an EBITDA multiple on the same business. Do not compare the two directly. Segment detail is in healthcare valuation multiples by sector.
Worked example: one $4.0 million EBITDA practice, three recap paths
Hypothetical. Every figure in this section is our arithmetic on stated assumptions, not market data. A multi-site specialty practice has $4.0 million of EBITDA and no debt. It is priced at 10.0x, inside Sikich's 9 to 11x indicative range for practices with $3 million to $5 million of EBITDA. Enterprise value is $4.0M × 10.0 = $40.0 million. With no debt, equity value is also $40.0 million.
Path A, minority recap. The owner sells 35% in a secondary sale. Pro rata control value of the stake is $40.0M × 35% = $14.0M. No dataset on this page prices minority stakes, so the discount to pro rata value is an open variable. We use 10% as an illustrative assumption and show the range.
| Discount to pro rata control value (illustrative) | 0% | 10% | 20% |
|---|---|---|---|
| Gross cash for 35% | $14.0M | $12.6M | $11.2M |
The tables below use the 10% case. The owner keeps 65% of the equity.
Path B, majority recap. A new holding company buys 100% of the practice for $40.0M. It funds the price with $16.0M of acquisition debt (4.0x EBITDA, 40% of the price) and $24.0M of equity. The sponsor contributes $18.0M of cash equity and the owner rolls $6.0M. The rollover is 15% of the $40.0M purchase price and buys $6.0M ÷ $24.0M = 25% of the holding company's equity. Gross cash at close is $40.0M minus $6.0M = $34.0M. The practice had no debt, so none is repaid.
Path C, dividend recap. The practice borrows 3.0x EBITDA, or $12.0M, and distributes it. The owner keeps 100%.
Costs, all on the same basis. Every path is shown gross, then net of assumed costs. Our assumptions: seller-side banker, legal and accounting costs of $0.6M on Path A and $1.0M on Path B, and lender and legal fees of 2% of the loan on Path C. Replace them with your own quotes.
| At close (hypothetical, our arithmetic) | Path A: minority | Path B: majority | Path C: dividend |
|---|---|---|---|
| Gross cash to owner | $12.6M | $34.0M | $12.0M |
| Assumed transaction costs | $0.6M | $1.0M | $0.24M (2%) |
| Net cash to owner, pre-tax | $12.0M | $33.0M | $11.76M |
| Owner's equity after close | 65% of the practice | 25% of the holding company | 100% of the practice |
| Debt | $0 | $16.0M at the holding company | $12.0M at the practice |
| Who controls the board | Owner, subject to investor seats and vetoes | Sponsor | Owner, within covenants |
After-tax view at close. Tax assumptions, stated once for all paths. The practice is an LLC taxed as a partnership. The owner has zero tax basis in the units. Paths A and B are sales of existing units, so the whole net amount is gain, taxed at a 25% starting assumption rate standing in for long-term capital gain plus state tax. The Path B rollover is structured as a tax-deferred exchange of practice units for holding company units. Path C is a debt-funded distribution, and whether it is taxed turns on the owner's basis and how the new debt is allocated, so we bracket it at 0% and 25%. Every after-tax figure below depends on these assumptions. A different basis, entity form, rollover treatment or debt allocation changes the result for that path, so have your tax adviser rerun each column on your own facts.
| After tax at close (hypothetical, our arithmetic) | Path A | Path B | Path C at 0% | Path C at 25% |
|---|---|---|---|---|
| Net cash, pre-tax | $12.0M | $33.0M | $11.76M | $11.76M |
| Assumed tax | $3.0M | $8.25M | $0 | $2.94M |
| After-tax cash | $9.0M | $24.75M | $11.76M | $8.82M |
| Value carried forward | 65% stake, never sold | $6.0M rollover, tax deferred | 100% stake, never sold | 100% stake, never sold |
If the Path B rollover does not qualify for deferral, the owner owes tax on $6.0M of value at close without receiving cash for it. At 25% that is $1.5M, which cuts Path B's after-tax cash to $23.25M. Settle the rollover structure in the LOI, not in the purchase agreement.
Path B second bite: debt-funded versus equity-funded add-ons
Assumptions, all ours:
- At the start of year one the sponsor buys small practices with $2.5M of combined EBITDA at 6.0x, inside Sikich's 5 to 7x indicative range for practices under $1 million of EBITDA. Cost: $15.0M.
- The platform runs at $6.5M of EBITDA for all five years. No organic growth, no integration costs.
- Each year: $0.60M of capex and $1.00M of tax distributions, leaving $4.90M of cash before interest.
- Interest is 10% on the opening debt balance. All cash after interest repays debt. Cash left after debt is fully repaid stays in the company. No interest income on cash.
- Exit at the end of year five at 11.0x: $6.5M × 11.0 = $71.5M enterprise value. No exit costs, no preferred return, no management fees.
- In the equity route, the sponsor funds the $15.0M of new equity at the original price per unit and the owner does not participate. Sponsor equity rises from $18.0M to $33.0M, total holdco equity rises from $24.0M to $39.0M, and the owner's $6.0M rollover is diluted from 25.0% to $6.0M ÷ $39.0M = 15.4%.
Cash-flow bridge (hypothetical, our arithmetic, $M):
| Year | Debt route: opening debt | Interest | Paydown ($4.90M minus interest) | Closing debt | Equity route: opening debt | Interest | Paydown | Closing debt |
|---|---|---|---|---|---|---|---|---|
| 1 | 31.00 | 3.10 | 1.80 | 29.20 | 16.00 | 1.60 | 3.30 | 12.70 |
| 2 | 29.20 | 2.92 | 1.98 | 27.22 | 12.70 | 1.27 | 3.63 | 9.07 |
| 3 | 27.22 | 2.72 | 2.18 | 25.04 | 9.07 | 0.91 | 3.99 | 5.08 |
| 4 | 25.04 | 2.50 | 2.40 | 22.64 | 5.08 | 0.51 | 4.39 | 0.69 |
| 5 | 22.64 | 2.26 | 2.64 | 20.00 | 0.69 | 0.07 | 0.69 | 0.00, with 4.14 cash retained |
| Year-five exit (hypothetical, our arithmetic) | Add-ons funded with debt | Add-ons funded with new equity |
|---|---|---|
| Debt at peak (start of year one) | $31.0M, 4.8x EBITDA | $16.0M, 2.5x EBITDA |
| Net debt at exit | $20.0M (3.1x) | $4.14M net cash |
| Equity value at exit | $71.5M minus $20.0M = $51.5M | $71.5M plus $4.14M = $75.64M |
| Total holdco equity contributed (initial $24.0M plus any new add-on equity) | $24.0M, no new equity | $24.0M initial + $15.0M new = $39.0M |
| Owner's share | 25.0% | $6.0M ÷ $39.0M = 15.4% |
| Owner's rollover value, pre-tax | $12.9M | $11.6M |
| Total to owner: $33.0M net at close plus rollover | $45.9M | $44.6M |
| Owner's rollover if the exit multiple is 9.0x instead | ($58.5M minus $20.0M) × 25% = $9.6M | ($58.5M plus $4.14M) × 15.4% = $9.6M |
| Value to owner of one turn of exit multiple | $6.5M × 25.0% = $1.6M | $6.5M × 15.4% = $1.0M |
At an 11.0x exit, debt funding is worth about $1.2M more to the owner. At a 9.0x exit the two routes tie. The debt route's edge is a bet on the exit multiple, paid for with 4.8x leverage at the start, close to the 5.2x entry leverage Sikich reports for PE-backed buyouts. A 20% drop in EBITDA right after the add-ons close would put that debt at $31.0M ÷ $5.2M = 6.0x. A sponsor preferred return on the new equity, or new equity issued at a higher price than the original, changes the result. Get the sponsor's add-on funding plan and the issue price for new equity in writing before you agree on rollover. Tax on the exit proceeds, including the deferred rollover gain, comes due at the sponsor's sale.
Path C coverage test
Assumptions: 10% interest, 5% annual amortization, $0.4M of maintenance capex and cash taxes or tax distributions at 15% of EBITDA. No owner distributions beyond tax distributions in the base calculation.
| Path C (hypothetical, our arithmetic) | Base case | Stress case |
|---|---|---|
| EBITDA | $4.0M | $3.2M (down 20%) |
| Interest rate | 10% | 12% |
| Interest on $12.0M | $1.20M | $1.44M |
| Scheduled principal (5%) | $0.60M | $0.60M |
| Maintenance capex | $0.40M | $0.40M |
| Cash taxes (15% of EBITDA) | $0.60M | $0.48M |
| Interest coverage: EBITDA ÷ interest | 3.33x | 2.22x |
| Fixed charge coverage: (EBITDA minus capex minus taxes minus owner distributions) ÷ (interest + principal) | $3.00M ÷ $1.80M = 1.67x | $2.32M ÷ $2.04M = 1.14x |
Interest coverage looks comfortable in both cases. Fixed charge coverage falls to 1.14x under stress, which leaves little room against a covenant minimum. Owner distributions make it worse. If the owner keeps taking $0.2M a year beyond tax distributions and the lender's definition deducts them, stress coverage drops to $2.12M ÷ $2.04M = 1.04x.
Work backward instead. Set a stress-case floor of 1.25x fixed charge coverage (our assumption, not a lender standard). Debt service under stress at 12% interest and 5% amortization is 17% of the loan each year. The maximum loan is $2.32M ÷ 1.25 ÷ 17% = $10.9M, not $12.0M. Lenders define fixed charges differently, so run your own figures through the definition in the commitment letter before you sign.
Paths A and C reach a year-five value close to Path B only if the owner can produce the same growth without a sponsor's acquisition capital. Test that assumption first.
Regulatory areas that can set the timeline
A recap that changes ownership or governance can draw several reviews, and any one of them can move the closing date or the structure.
- Federal antitrust premerger notice. Larger deals may require a filing with the FTC and DOJ and a waiting period before closing. Platform add-on programs draw closer scrutiny.
- State healthcare transaction notice laws. A growing number of states require advance notice of private equity, MSO or change-of-control deals, and some reach minority investments with strong governance rights.
- Medicare enrollment and change of ownership. A majority recap can trigger CMS change-of-ownership filings, and prior ownership changes can limit timing, especially in home health and hospice.
- Federal referral and self-referral rules. Physician owners who refer, physician investors and post-close compensation all need review by your attorney. The HHS Office of Inspector General publishes compliance guidance.
- Corporate practice of medicine. State rules on who may own a clinical entity often decide whether the investor buys into the practice or into an MSO.
- Securities offering and broker-dealer rules. Selling a minority stake to several investors is a securities offering, and anyone paid to find investors may need to be registered. Check any banker or placement agent on FINRA BrokerCheck.
- Tax treatment. Rollover deferral and the tax on a dividend distribution depend on entity form and structure, as the worked example shows.
High-risk area: questions to take to your own attorney before you sign an LOI. Bring your entity chart and ask:
- Which federal or state reviews could apply to this deal, and why? Ask this first so the closing timeline is built around the longest review.
- Do the investor's board seats and consent rights count as a change of control under any review that applies? Broad vetoes can pull a minority deal into review.
- Does any state where we operate limit who may own the clinical entity, and does that push the deal into an MSO structure?
- Will a majority recap trigger Medicare change-of-ownership filings, and do prior ownership changes limit when we can close?
- How should physician investors who refer be treated, and does post-close compensation raise risk under federal referral and self-referral rules?
- Is the minority sale a securities offering, and is everyone paid to find investors properly registered?
- Does the rollover structure support tax deferral, and how would a dividend distribution be taxed given our basis and entity form?
- How have states where we operate handled PE or MSO deals in our segment, and what other topics should we raise for our provider type?
The answers depend on your states, provider type and structure. Treat this list as a starting point, not legal advice.
Buyer-side diligence on these points is covered in the healthcare compliance due diligence guide, and physicians who both refer and invest are covered in raising capital from physician investors.
Recap sequence: what to settle at each stage, from first call to close
Most value in a recap is won or lost before the purchase agreement. This order keeps the owner from negotiating price before the terms that decide what the price is worth.
| Stage | What to settle | What you should have in hand |
|---|---|---|
| Before any outreach | Pick the path using the decision table. Finish the readiness items. List every state and entity you operate in | Defended adjusted EBITDA, clean cap table, a target range for cash at close |
| Choosing advisers | Hire the banker, deal counsel and tax adviser before talking to investors. Confirm how each is paid. Look up any banker or placement agent on BrokerCheck | Engagement letters with fee terms and a tail period you understand |
| Comparing indications | Compare offers on after-tax cash at close plus the expected value of retained or rolled equity, as in the worked example, not on headline multiple | One table per offer: net cash, after-tax cash, equity retained, debt, board control |
| Negotiating the LOI | Lock rollover structure, equity class, preferred return, add-on funding plan, new-equity issue price, consent list and distribution policy | An LOI that answers every point in the term sheet list below |
| Diligence | Lender commitment and coverage tests on your own figures. Map every review that could move the closing date | A closing timeline built around the longest review period |
| Signing to close | Hold the business steady. Producer retention and payer contracts carry the rollover value | No surprises in the bring-down of EBITDA |
Process detail is in the healthcare M&A process guide. If you plan to sell a minority stake to several investors, read capital raising for healthcare companies and how to choose a healthcare investment banker first.
The recap document binder: what to hand your advisers in week one
Advisers can only flag structure, timing and price issues in documents they have seen. An owner who delivers this binder before the first term sheet gets answers while there is still room to change the structure.
| Document | Effect on the recap |
|---|---|
| Entity chart showing every legal entity, its owners and the states it operates in | Sets which reviews and consents apply and whether an MSO structure is in play |
| Operating agreements, buy-sell agreements and any prior investor documents | Existing vetoes, rights of first refusal or buyout formulas can block or reprice the deal |
| Physician and owner employment and compensation agreements | Set post-close EBITDA, retention and the restrictive covenants tied to rollover |
| Management services or administrative services agreements | Fee terms and control provisions shape how an investor can buy in |
| List of physicians who own equity or will invest, with their referral relationships | Physician investors who refer change how the deal is structured and reviewed |
| Medicare enrollment dates, prior change-of-ownership dates and licenses by state | Can set the closing date and whether a majority recap works now or later |
| Top payer contracts with assignment and change-of-control clauses | A payer consent can become a closing condition |
| Existing loan documents | Change-of-control, restricted payment and prepayment terms affect all three paths |
| Real estate deeds and leases, including related-party leases | Drive sale-leaseback options and the rent that sets EBITDA |
| Three years of tax returns and each owner's basis estimate | Decide the after-tax figures, including whether Path C lands near 0% or 25% |
| Coding audit and any payer or government inquiries | Become indemnity, escrow and price issues if found late |
Term sheet points that decide what a recap pays
- Equity class. Is the rollover or the minority stake common or preferred, and does it rank pari passu with the sponsor's?
- Liquidation preference and preferred return. Both are paid before common equity at exit.
- Rollover tax structure. Confirm the rolled portion is structured for deferral and that the holding company form supports it.
- Add-on funding plan. Ask whether acquisitions will be funded with debt or new equity, and at what price new equity will be issued.
- Warrants. A warrant that pays out at a later recap or sale reduces every other holder's proceeds.
- Drag-along and tag-along. These decide who can force a sale and who can join one.
- Put and call rights. These set the timing and the price formula.
- Board seats and consent rights. Get the full veto list in writing.
- Physician compensation after close. Agree on the pay model before signing, since it sets both post-close EBITDA and producer retention.
- Restrictive covenants. Check the length, the geography and whether they are tied to the rollover or to employment.
More red flags are in the LOI and term sheet red flags checklist. Recap structures for practices are covered in the physician practice recapitalization white paper.
Questions owners ask
What is the difference between a recapitalization and a sale?
A sale transfers the whole business and ends the owner's economic stake. A recapitalization changes the ownership or debt mix while the owner stays in. In a minority recap the owner sells a non-controlling stake, and the governing documents decide how much control the owner keeps. In a majority recap the owner sells control to a new holding company and rolls part of the proceeds into it. In a dividend recap no equity changes hands. The company borrows and distributes the cash.
How much equity do owners roll in a majority recap?
Rollover is negotiated deal by deal. It turns on how much alignment the sponsor wants and how much cash the owner needs. Holding company debt changes the math. In this page's hypothetical, the owner rolls $6.0 million, which is 15% of the $40.0 million purchase price, and receives 25% of the holding company's equity because acquisition debt funds $16.0 million, or 40%, of the price. Before you agree to a rollover amount, model the equity class, the preferred return, how add-ons will be funded and the tax treatment of the rolled portion.
Does a minority recap trigger state healthcare transaction notice laws?
It can. Whether a state review applies depends on where you operate, the type of provider and how much control the investor's board seats and consent rights carry. Some state laws also reach management services organizations and asset transfers. Map every state and entity you operate in before you sign a term sheet, and build the longest review period into the closing timeline.
When does a dividend recap make sense for a healthcare company?
It works when cash flow is stable, existing debt is low, payer mix is diversified and the owner wants liquidity without giving up equity or control. It works poorly when reimbursement cuts are likely, when the company needs growth capital for add-ons, or when covenants would leave little headroom. Size the debt to fixed charge coverage at a stressed rate and a stressed EBITDA, with ongoing owner distributions counted, not to sponsor buyout leverage.
Sources
- CMS, National Health Expenditure fact sheet (2024 data, 2025 to 2034 projections)
- Sikich, Q3 2026 US healthcare M&A market update and year-end outlook (cites PitchBook data)
- BuckheadFMV, Healthcare Services M&A Valuation Multiples, 187 control transactions, Jan 2023 to Oct 2026
- Axia Growth, healthcare sector closed small-business sales by deal size, data as of Oct 28, 2026
- Aswath Damodaran, NYU Stern, EV/EBITDA multiples by sector (US), January 2026
- Private Equity Stakeholder Project, Private Equity Healthcare Deals: 2025 in Review (PitchBook and LevinPro HC data)
- Becker's ASC Review, outpatient specialties in 2025 deal activity (PESP data)
- Becker's Hospital Review, hospital M&A through Q3 2026 (Kaufman Hall data)
- Kaufman Hall, Q3 2026 M&A Quarterly Activity Report press release, Oct 13, 2026
- U.S. Small Business Administration, 7(a) loan program overview page, accessed November 2026
- SEC EDGAR full-text search (Form D filings)
- FINRA BrokerCheck
- Federal Trade Commission, Premerger Notification Program
- HHS Office of Inspector General, compliance guidance